-
Tytuł:
-
[Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
-
Autorzy:
-
Marquette T; Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite 13009 Marseille, France.
Walz J; Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite 13009 Marseille, France.
Rybikowski S; Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite 13009 Marseille, France.
Maubon T; Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite 13009 Marseille, France.
Branger N; Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite 13009 Marseille, France.
Fakhfakh S; Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite 13009 Marseille, France.
Verde KL; Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite 13009 Marseille, France.
Dermeche S; Service d'Oncologie Médicale, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite, 13009 Marseille, France.
Gravis G; Service d'Oncologie Médicale, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite, 13009 Marseille, France.
Pignot G; Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, 232, boulevard de Sainte Marguerite 13009 Marseille, France. Electronic address: .
-
Transliterated Title:
-
Tolérance de la thermo-chimiothérapie par HIVEC® chez les patients réfractaires au BCG.
-
Źródło:
-
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie [Prog Urol] 2020 Jan; Vol. 30 (1), pp. 35-40. Date of Electronic Publication: 2019 Nov 28.
-
Typ publikacji:
-
Journal Article
-
Język:
-
French
-
Imprint Name(s):
-
Publication: Paris : Progrès en urologie, S.A.R.L
Original Publication: Paris : F.I.I.S.,
-
MeSH Terms:
-
Antibiotics, Antineoplastic/*administration & dosage
BCG Vaccine/*administration & dosage
Mitomycin/*administration & dosage
Urinary Bladder Neoplasms/*drug therapy
Administration, Intravesical ; Adult ; Aged ; Aged, 80 and over ; Antibiotics, Antineoplastic/adverse effects ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Hyperthermia, Induced ; Male ; Middle Aged ; Mitomycin/adverse effects ; Prospective Studies ; Surveys and Questionnaires ; Urinary Bladder Neoplasms/pathology
-
Contributed Indexing:
-
Keywords: BCG; BCG-refractory; Bladder cancer; Efficacité; Efficiency; Recurrence; Récidive; Réfractaire; Safety; Thermo-chemotherapy; Thermo-chimiothérapie; Tolérance; Tumeur de vessie
-
Substance Nomenclature:
-
0 (Antibiotics, Antineoplastic)
0 (BCG Vaccine)
50SG953SK6 (Mitomycin)
-
Entry Date(s):
-
Date Created: 20191203 Date Completed: 20201015 Latest Revision: 20201015
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.purol.2019.11.001
-
PMID:
-
31787540
-
Introduction: There is increasing evidence that Hyperthermic Intravesical Chemotherapy is an effective treatment for non-muscle invasive bladder cancer (NMIBC). HIVEC (COMBAT BRS system) is an innovative hyperthermia delivering device. The aim of our study is to evaluate tolerance and safety of HIVEC in patients with BCG-refractory NMIBC.
Materials and Methods: In this study, we included 22 patients between January 2017 and April 2018. The treatment consisted in a weekly instillation of Hyperthermic Mitomycin for a total of 6 weeks, with a follow-up every 3 months. In order to evaluate the tolerance, patients filled a questionnaire before each instillation. We analyzed collected data to evaluate safety and efficiency of the treatment after one year.
Results: Among 22 patients included, no patient suffered from severe side effects. The minor side effects reported were : urinary urgency (40,1 %), urinary pain (40,1%), macroscopic hematuria (4,5%). The IPSS score didn't significantly varied before and after instillations (mean IPSS: 10.8 versus 10.1, p=0.77). The mean follow-up was 11.2 months. The recurrence rate was 27,3% with an average time to recurrence of 7.36 months. Two patients (9.1%) presented a progression to muscle-invasive disease. Four patients (18,2%) had a radical cystectomy.
Conclusion: Hyperthermic Mitomycin using the HIVEC® device is a rather safe and well tolerated treatment. Efficiency remains partial as 27.3% of patients experienced recurrence during the first year. These data should be confirmed by prospective multicentric studies.
(Copyright © 2019. Published by Elsevier Masson SAS.)
